SCHEMBL18005014

SCHEMBL18005014

N#Cc1[nH]nnc1-c1csc(-c2ccc(F)cc2)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.49
▸ AR P10275 1/20 0.49
▸ CYP19A1 P11511 1/20 0.44
▸ CDC25A P30304 1/20 0.42
▸ CDC25B P30305 1/20 0.42
▸ CDC25C P30307 1/20 0.42
▸ PPM1D O15297 1/20 0.40
▸ SREBF2 Q12772 1/20 0.39
▸ LMNA P02545 3/20 0.39
▸ TDP1 Q9NUW8 1/20 0.38
▸ MAPT P10636 2/20 0.37
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ NPSR1 Q6W5P4 2/20 0.37
▸ POLB P06746 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ HTT P42858 2/20 0.37
▸ ALOX5 P09917 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ ADORA1 P30542 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18005024 0.88 CDC25A (0.55) KDM4EARCDC25ACDC25BCDC25C
SCHEMBL18005019 0.87 RAB9A (0.49) KDM4ECDC25ACDC25BCDC25CSREBF2
SCHEMBL18005984 0.87 RAB9A (0.46) KDM4EARCYP19A1CDC25ACDC25B
SCHEMBL16399142 0.87 KDM4E (0.49) KDM4ECYP19A1CDC25ACDC25BCDC25C
SCHEMBL18005007 0.87 CYP1A1 (0.35) KDM4EARCYP19A1CDC25ACDC25B
SCHEMBL18005982 0.87 KMT2A (0.47) KDM4EARCYP19A1CDC25ACDC25B
SCHEMBL18004999 0.86 KDM4E (0.43) KDM4EARCDC25ACDC25BCDC25C
SCHEMBL18005013 0.86 RAB9A (0.44) KDM4EARCDC25ACDC25BCDC25C
SCHEMBL18005015 0.84 KDM4E (0.51) KDM4ECYP19A1CDC25ACDC25BSREBF2
SCHEMBL18005026 0.83 EIF4E (0.39) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
US-10626095-B2 Cyanotriazole compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-04-21 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2016-08-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10626095-B2 Cyanotriazole compounds CS, PC, ACAT1 KDM4E 2681/4885AR 3449/4885CYP19A1 653/4885
US-20160229816-A1 CYANOTRIAZOLE COMPOUNDS CS, PC, ACAT1 KDM4E 2681/4885AR 3449/4885CYP19A1 653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback